New migraine pill shows promise in prevention study
NCT ID NCT06409832
First seen Jan 22, 2026 · Last updated Jun 12, 2026 · Updated 19 times
Summary
This study is testing a drug called rimegepant to see how well it prevents migraines in 100 adults who have at least 4 migraine days per month. Researchers will track changes in migraine frequency over 3 to 12 months. The goal is to reduce the number of migraine days, not to cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
IRCCS National Neurological Institute "C. Mondino" Foundation
RECRUITINGPavia, Pavia, 27100, Italy
Contact Email: •••••@•••••
-
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
RECRUITINGFlorence, Florence, 50134, Italy
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.